Acquisition by Blackwell Kimberly of 44000 shares of Century Therapeutics at 2.69 subject to Rule 16b-3
IPSC Stock | USD 1.10 0.05 4.76% |
About 56% of all Century Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Century Therapeutics suggests that some traders are interested. The current market sentiment, together with Century Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Century Therapeutics stock news signals to limit their universe of possible portfolio assets.
Century |
Filed transaction by Century Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Century Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Century Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Century Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Century Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Century Therapeutics Fundamental Analysis
We analyze Century Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Century Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Century Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Century Therapeutics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Century Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Century Therapeutics stock to make a market-neutral strategy. Peer analysis of Century Therapeutics could also be used in its relative valuation, which is a method of valuing Century Therapeutics by comparing valuation metrics with similar companies.
Peers
Century Therapeutics Related Equities
GBIO | Generation Bio | 10.19 | ||||
NKTX | Nkarta | 9.22 | ||||
PASG | Passage Bio | 8.20 | ||||
CCCC | C4 Therapeutics | 7.92 | ||||
CGEM | Cullinan Oncology | 7.71 | ||||
GLUE | Monte Rosa | 6.45 | ||||
MLYS | Mineralys Therapeutics, | 4.31 | ||||
ERAS | Erasca | 3.67 | ||||
STOK | Stoke Therapeutics | 3.36 | ||||
EWTX | Edgewise Therapeutics | 2.57 | ||||
BPMC | Blueprint Medicines | 1.36 | ||||
KROS | Keros Therapeutics | 0.65 | ||||
KZR | Kezar Life | 2.15 | ||||
RLAY | Relay Therapeutics | 2.35 |
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |